Adma Biologics Inc (NASDAQ:ADMA) currently has a daily average trading volume of 2.54M but it saw 2981156 shares traded in last market. With a market cap of 1.44B USD, the company’s current market price of $6.20 came rising about 2.65 while comparing to the previous closing price of $6.04. In past 52 weeks, the stock remained buoying in the range of price level as high as $6.76 and as low as $3.06.
Taking a look at 20-day trading activity of Adma Biologics Inc (ADMA) gives us an average price of $6.28, while its current price level is -8.28% below from 52-week high level whereas it is 102.61% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $5.90 while that of 200 days or SMA-200 reads an average of $4.46. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.37% during that period while stretching the period over a month that decreases to 3.65%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 52.30 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Raymond James which resumed the stock as “Strong Buy” in its note to investors issued on July 19, 2023, recommending a price target of $5 for it. Raymond James issued its recommendations for the stock as it upgraded the price target for the stock is $5.
Over the week, ADMA’s stock price is moving -0.32% down while it is 0.16% when we observe its performance for the past one month. Year-to-date it is 37.17% up and over the past year, the stock is showing an upside performance of 85.63%.
Currently, Adma Biologics Inc’s total number of outstanding shares is 226.06M. Company’s return on investment (ROI) stands at -10.25% and return on equity (ROE) at -19.67%. It has a 12.40 of forward P/E ratio. Stock’s beta reads 0.45. Stock has a price to book (P/B) ratio of 10.37 while price to sale or P/S ratio amounts to 5.57. Its return on asset (ROA) is -8.33% on average.
